Business Context and Reporting Period
This Form 8-K, filed on August 28, 2026, reports on events occurring on August 27, 2026, for Simulations Plus, Inc. (SLP). The filing details the results of a Special Meeting of Shareholders held to vote on proposals related to a proposed merger with SP Evolution HoldCo II, LLC, an affiliate of Altaris, LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and transaction events. It does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
Shareholders approved three key proposals at the Special Meeting. Approximately 76.83% of outstanding shares were represented at the meeting.
- Proposal 1 (Merger Agreement): Approved. Shareholders voted to adopt the Agreement and Plan of Merger.
- Votes For: 14,735,712
- Votes Against: 771,288
- Votes Abstaining: 32,537
- Proposal 2 (Merger-Related Compensation): Approved on an advisory, non-binding basis.
- Votes For: 10,930,973
- Votes Against: 1,174,280
- Votes Abstaining: 3,434,284
- Proposal 3 (Adjournment): Approved, though not utilized as sufficient votes were obtained for the Merger Agreement.
- Votes For: 14,444,277
- Votes Against: 986,000
- Votes Abstaining: 109,260
Outlook, Risks, and Contingencies
The closing of the Merger remains subject to the satisfaction or waiver of customary conditions, specifically including the receipt of certain regulatory approvals in France. The filing includes extensive forward-looking statements regarding the expected timing and benefits of the Merger.
Key risks identified include:
- Failure to obtain necessary regulatory approvals or satisfaction of closing conditions.
- Disruption of management time and ongoing business operations.
- Potential adverse effects on market price, customer retention, and key personnel retention.
- Risk of termination of the Merger Agreement, potentially triggering termination fees.
- Competing offers, unexpected costs, and potential litigation.
- Broader economic, political, and industry-specific risks affecting the pharmaceutical and biotechnology sectors.
Investor Verification Checklist
- Verify the status of the required regulatory approvals in France, which are a condition precedent to closing.
- Review the Definitive Proxy Statement on Schedule 14A (filed July 22, 2026) for detailed terms of the Merger Agreement and compensation plans.
- Monitor for any announcements regarding the expected closing date or potential delays.
- Assess the risk of competing offers or termination of the agreement based on the disclosed risk factors.